88 results
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
31 Oct 19
Agios Reports Business Highlights and Third Quarter 2019 Financial Results
7:39am
of Medicine; Updated Data from Extension Phase to be Presented at American Society of Hematology Annual Meeting –
CAMBRIDGE, Mass., October 31, 2019 … isocitratedehydrogenase-1 (IDH1) mutant cholangiocarcinoma at the European Society for Medical Oncology Congress in September, demonstrating significant improvement
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
1 Aug 19
Agios Reports Business Highlights and Second Quarter 2019 Financial Results
7:29am
at the 2019 American Society of Clinical Oncology Annual Meeting. The data presentations can be foundhere.
Began dosing patients in the Phase 1 dose … Society for Medical Oncology Congress taking place in Barcelona, Spain from September27-October 1, 2019.
Data from the single agent dose-escalation
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
30 Apr 20
Agios Reports First Quarter 2020 Financial Results and Provides Update on Business Operations andCOVID-19 Response
7:19am
in Sickle Cell Disease on Track forMid-2020; Data to be Submitted for Presentation at the American Society of Hematology Annual Meeting –
– Cash … for presentation at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting in May, which is being held virtually.
Data from the Phase 2 study
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
16 Nov 18
Agios Presents Updated Data from Phase 1 Dose-Escalation Study ofAG-881 in Patients with IDH Mutant Positive Advanced Glioma
4:01pm
updated data from the ongoing Phase 1 study evaluating single agentAG-881 in advanced glioma. The data were featured in an oral presentation at the Society … at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. As of the updated July 20, 2018 data cut-off, study design, enrollment and baseline
8-K
EX-99.2
AGIO
Agios Pharmaceuticals Inc
16 Oct 15
Regulation FD Disclosure
12:00am
and AG-120 in advanced hematologic malignancies have been accepted for presentation at the American Society of Hematology (ASH) Annual Meeting … cells. AML incidence significantly increases with age, and according to the American Cancer Society, the median age of onset is 66. Less than 10 percent
8-K
EX-99.1
54dras
2 Aug 18
Agios Reports Second Quarter 2018 Financial Results
7:28am
8-K
EX-99.1
qff4nsweq8kf
16 Jun 14
Other Events
12:00am
8-K
EX-99.1
2i6e ipn13r3l7fh6w7
4 May 18
Results of Operations and Financial Condition
7:07am
8-K
EX-99.1
venhoct rreqqyi2
1 Nov 18
Agios Reports Third Quarter 2018 Financial Results
7:45am
8-K
yh40e8j3fl8 ok42n2
16 Nov 18
Agios Presents Updated Data from Phase 1 Dose-Escalation Study ofAG-881 in Patients with IDH Mutant Positive Advanced Glioma
4:01pm
8-K
EX-99.1
bjqfa2pkts rmee
8 Dec 14
Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies
12:00am
8-K
azxb76qdok de
30 Sep 19
Other Events
11:13am
8-K
v7opxn32 0gk1
8 Dec 14
Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies
12:00am
8-K
kjtym
3 Jun 19
Other Events
4:02pm
8-K
9ndv53e
3 Dec 18
Other Events
4:03pm
8-K
w7805 3rz7czg03
22 Nov 19
Other Events
5:01pm
8-K
EX-99.1
awjkhvhan ef
7 Aug 14
Agios Pharmaceuticals Reports Second Quarter 2014 Financial Results
12:00am
8-K
tj9trw
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
8-K
EX-99.1
uzd22qqfi px8r3sziu
25 Feb 21
Agios Reports Fourth Quarter and Full Year 2020 Financial Results
7:17am
8-K
EX-99.1
53mq0uoy3bu3p
7 Nov 14
Agios Pharmaceuticals Reports Third Quarter 2014 Financial Results
12:00am